Brief: Modus Therapeutics Opens Second Study Site For Phase IIA CKD-Anemia Study
02/04/2025 14:04
April 2 (Reuters) - Modus Therapeutics Holding AB MODTX.ST: OPENS SECOND STUDY SITE FOR PHASE IIA CKD-ANEMIA STUDY NEW STUDY SITE LOCATED IN PAVIA, ITALY Source text: ID:nMFN1TLxdt Further company coverage: MODTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Modus Therapeutics Holding AB
See all newsBrief: Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia
Brief: Modus Gets SEK 0.13 Mln Through Exercise Of Warrants
Brief: Modus Therapeutics Resolves On Directed Share Issue Of 20 Million Shares
Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Brief: Modus Therapeutics Q2 Net Income SEK -4.645 Million